Sergey Terushkin, MD, FACS Key Takeaways: Mounjaro (tirzepatide) targets GIP + GLP-1 receptors , while Ozempic (semaglutide) targets GLP-1 only Clinical studies show greater average weight loss with tirzepatide in many patients Both medications require BMI 30 or 27 with weight-related conditions Common side effects include nausea, GI discomfort, and appetite changes , usually improving with dose adjustment Insurance coverage varies more common for diabetes than weight loss Prescription required treatment must be doctor-guided and medically supervised If you are deciding between Mounjaro and Ozempic for weight loss in 2026, the key difference is that tirzepatide (Mounjaro) activates two metabolic pathways (GIP + GLP-1), while semaglutide (Ozempic) activates one (GLP-1) which may impact weight loss outcomes and tolerability
By mimicking this hormone, Wegovy can help reduce appetite, support smaller portion sizes, and make it easier to maintain a calorie deficit , which supports gradual weight loss
The Refill, Issue 5: FDA UpdatesSemaglutide Approval, Ketamine in Surgery, and 7-OH Limits Hello
Researchers study Retatrutide in several ways
The type matters
Wegovy'nin etken maddesi semaglutide, bir GLP-1 reseptr antagonistidir
